| Budget Amount *help |
¥23,400,000 (Direct Cost: ¥18,000,000、Indirect Cost: ¥5,400,000)
Fiscal Year 2020: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2019: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2018: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2017: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
|
|---|
| Outline of Final Research Achievements |
As a new base-editing technology, we have succeeded in creating an artificial enzyme that can be expressed in cells without causing genomic instability using DNA glycosylase as a matrix, and can debase thymine only in targeted regions. This enabled the conversion of thymine to other bases. Furthermore, they increased the efficiency by adding factors involved in post-debase repair. In order to increase the versatility of the enzyme, they were able to find a way to make it work in combination with CRISPR variants.
Translated with www.DeepL.com/Translator (free version)
|
